BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IPH4502 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IPH4502\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06781983-2557@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:IPH4502: Phase 1 readout est. (NCT06781983)
DESCRIPTION:IPH4502\, phase 1.\nStudy: Safety and Tolerability of IPH4502 i
 n Patients With Advanced Solid Tumors\nEstimated primary completion: April
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/iph4502#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06781983
URL:https://assetmemo.bio/drug/iph4502#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
